Preclinical concepts and results with the GABAA antagonist S44819 in a mouse model of middle cerebral artery occlusion
Dirk M. Hermann
Barbara Saba
Aurore Sors
Claudio L. Bassetti
摘要：Recent advancements in recanalizing therapies, i.e., the combi-nation of thrombolytic drugs with interventional thrombecto-my, have considerably improved neurological outcome in isch-emic stroke patients. Despite this progress, the large majority of stroke patients still exhibit neurological deficits in the long run, and ischemic stroke continues to be the most frequent cause of long-term disability. Hence, there is an unmet need for therapies that allow enhancing neurological recovery and brain plasticity in the post-acute stroke phase (Hermann and Chopp, 2012). Preclinical studies, e.g., delivering growth factors (Reit-meir et al., 2011) or neural precursor cells (NPC) (Bacigaluppi et al., 2016), have shown that brain plasticity can be successfully stimulated in the post-acute stroke phase, resulting in function-al neurological improvements. These findings raised the ques-tion whether it is possible to promote neurological recovery and brain plasticity in stroke patients.
机标关键词：
资助基金：Institut de Recherches Internationales Servi-er, Suresnes, France and Deutsche Forschungsgemeinschaft (HE3173/3-1 and HE3173/11-1)Institut de Recherches Internationales Servi-er, Suresnes, France and Deutsche Forschungsgemeinschaft ( to DMH)
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1517-1518 )